Assetmark Inc. Acquires 27,220 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Assetmark Inc. lifted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 230.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,025 shares of the biotechnology company's stock after purchasing an additional 27,220 shares during the period. Assetmark Inc.'s holdings in Sarepta Therapeutics were worth $4,874,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Fifth Third Wealth Advisors LLC acquired a new stake in Sarepta Therapeutics during the 2nd quarter worth $607,000. Teachers Retirement System of The State of Kentucky acquired a new position in Sarepta Therapeutics in the second quarter valued at $4,771,000. Securian Asset Management Inc. acquired a new position in Sarepta Therapeutics in the second quarter valued at $1,187,000. Natixis Advisors LLC acquired a new position in Sarepta Therapeutics in the second quarter valued at $1,918,000. Finally, Oppenheimer Asset Management Inc. increased its stake in Sarepta Therapeutics by 32.0% in the first quarter. Oppenheimer Asset Management Inc. now owns 3,604 shares of the biotechnology company's stock valued at $467,000 after purchasing an additional 874 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. William Blair upgraded shares of Sarepta Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. Piper Sandler dropped their price target on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an "overweight" rating on the stock in a research note on Thursday, August 8th. Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They set a "buy" rating and a $165.00 price target on the stock. UBS Group boosted their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a "buy" rating in a research note on Tuesday, September 17th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $205.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, November 7th. One investment analyst has rated the stock with a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Sarepta Therapeutics currently has an average rating of "Buy" and a consensus target price of $181.33.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock traded down $3.52 during midday trading on Tuesday, reaching $114.32. The company's stock had a trading volume of 1,110,094 shares, compared to its average volume of 1,233,550. Sarepta Therapeutics, Inc. has a 52 week low of $76.61 and a 52 week high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.19 and a debt-to-equity ratio of 0.93. The business has a 50-day moving average price of $125.56 and a 200-day moving average price of $132.90. The stock has a market cap of $10.92 billion, a PE ratio of 94.27 and a beta of 0.81.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Michael Andrew Chambers purchased 37,038 shares of the company's stock in a transaction on Friday, August 16th. The shares were purchased at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now owns 284,034 shares in the company, valued at $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael Andrew Chambers acquired 37,038 shares of Sarepta Therapeutics stock in a transaction on Friday, August 16th. The stock was acquired at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the purchase, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.